Welcome to our dedicated page for Pharmather Holdings news (Ticker: PHRRF), a resource for investors and traders seeking the latest updates and insights on Pharmather Holdings stock.
PharmaTher Holdings Ltd. (OTCQB: PHRRF, CSE: PHRM) generates news centered on its ketamine-focused pharmaceutical programs, drug delivery platforms, and related asset monetization activities. Company announcements describe a specialty pharmaceutical and life sciences business focused on unlocking the pharmaceutical and therapeutic potential of ketamine, psychedelics, and GLP-1 drugs, particularly for neuropsychiatric, mental health, pain, neurological, and obesity-related disorders.
News updates cover several recurring themes. One major area is the development of ketamine-based therapies, including a program for levodopa-induced dyskinesia in Parkinson's disease (LID-PD) that the company is preparing to advance under the FDA 505(b)(2) pathway toward a Phase 3 strategy. Releases describe regulatory planning, prior Phase I/II data, intellectual property coverage, and discussions with potential pharmaceutical partners. Another frequent topic is the evolution of a long-acting injectable ketamine franchise under an exclusive evaluation and option-to-license agreement with Oakwood Laboratories, which is intended to address neuropsychiatric indications such as treatment-resistant depression and major depressive disorders.
PharmaTher also issues news about its PharmaPatch™ microneedle patch platform, including initiatives to deliver ketamine, psychedelic compounds, and GLP-1 drugs, and its expansion into GLP-1 therapies for the potential treatment of obesity. Additional updates highlight the Digital Health AI division, featuring KetaVault™ and KetAImine™, which are presented as ketamine data and AI discovery platforms designed to generate new indications and combination programs.
Corporate communications further report on the FDA-approved ketamine ANDA, its sale to a sterile-injectables partner with milestone and profit-sharing economics, and the company's broader asset strategy, including its 49% equity interest in Sairiyo Therapeutics Inc. Investors and observers who follow PHRRF news can use this page to review company statements on clinical plans, regulatory interactions, partnering discussions, and platform expansions as disclosed in official releases.
PharmaTher Holdings Ltd. (OTCQB: PHRRF) has formed a collaboration with MediSynergics, LLC to develop patented ketamine derivatives aimed at treating pain and CNS disorders. Initial research shows these derivatives could potentially offer better efficacy and fewer side effects than traditional ketamine, making them suitable alternatives to opioids. The partnership also aims to explore next-generation psychedelics like psilocybin and DMT. PharmaTher is currently in a Phase 2 FDA study using ketamine to treat Parkinson's disease and is developing a microneedle patch for psychedelic delivery.
PharmaTher Holdings Ltd. (OTCQB: PHRRF) has filed an application with the FDA for Orphan Drug Designation for ketamine to treat amyotrophic lateral sclerosis (ALS). ALS, affecting around 50,000 in the U.S. and Europe, currently has no cure and a limited life expectancy post-diagnosis. Ketamine's promising preclinical research indicates it may preserve muscle function and increase life expectancy in ALS patients. If approved, ketamine could achieve over USD $1 billion in peak sales, offering significant incentives and marketing exclusivity to PharmaTher.
PharmaTher Holdings Ltd. (CSE: PHRM, OTCQB: PHRRF) has appointed Professor Matthew Macaluso, D.O. as a scientific and clinical advisor to enhance its clinical research programs focused on ketamine for treating major depressive disorders and ALS. With over ten years of experience in clinical trials, Macaluso's expertise includes leading over 60 trials involving treatment-resistant depression. His involvement aims to guide PharmaTher’s initiatives for regulatory approvals and clinical strategies, further developing ketamine's potential in neurology and psychiatry.
PharmaTher Holdings Ltd. announced FDA approval for its IND application to initiate a Phase 2 clinical trial of ketamine aimed at treating levodopa-induced dyskinesia in Parkinson’s disease patients. The trial will commence in Q3-2021 at up to eight sites across the U.S., enrolling 36 participants. The global market for Parkinson's treatment is projected to grow from $5 billion in 2019 to $7.5 billion by 2025, with the U.S. opportunity for this specific treatment exceeding $3 billion. CEO Fabio Chianelli emphasized the milestone as a step towards establishing PharmaTher as a leader in psychedelic-based therapeutics.
PharmaTher Holdings Ltd. (CSE: PHRM, OTCQB: PHRRF) has filed a provisional patent application for ketamine as a treatment for Type 2 diabetes and obesity, utilizing its AI platform, panaceAI™. The company is pursuing an IND application with the FDA for a Phase 2 trial of ketamine targeting Parkinson’s disease.
PharmaTher is also investigating other psychedelics like DMT, MDMA, and LSD for clinical development. The company aims to commercialize its findings through internal development or partnerships, enhancing its patent portfolio.
PharmaTher Holdings Ltd. announced the submission of an Investigational New Drug (IND) application to the FDA for a Phase 2 clinical trial examining low-dose ketamine's efficacy in treating levodopa-induced dyskinesia in Parkinson’s disease patients. This application marks a significant milestone for the company in its efforts to commercialize ketamine. The trial aims to enroll 36 subjects across multiple U.S. sites, with the primary endpoint being the change in the Unified Dyskinesia Rating Scale total score after 8 weeks. A positive trial outcome may lead to a pivotal Phase 3 study.
PharmaTher Inc., a subsidiary of Newscope Capital Corporation (CSE: PHRM, OTCQB: PHRRF), has announced a research partnership with Queen's University Belfast to develop a microneedle patch for delivering ketamine and its proprietary formulation, KETABET™. This novel delivery method aims to improve treatment for neuropsychiatric and pain disorders, addressing issues associated with traditional ketamine administration. The patented technology promises increased drug delivery efficiency and incorporates anti-abuse features. Progress in clinical development is anticipated to meet unmet medical needs in mental health.
PharmaTher, a subsidiary of Newscope Capital Corporation (CSE: PHRM, OTCQB: PHRRF), has secured an exclusive license from The University of Kansas for the development of ketamine as a treatment for amyotrophic lateral sclerosis (ALS). Preclinical studies indicate that ketamine may enhance muscle function and prolong life expectancy in ALS patients. Currently, ALS lacks a cure, with FDA-approved treatments failing to significantly slow disease progression. The company plans to seek FDA orphan drug designation and conduct Phase II clinical trials this year.
Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF) has announced that their shares are now eligible for electronic clearing and settlement through The Depository Trust Company (DTC) in the U.S. This development is expected to enhance accessibility and visibility for U.S. investors, potentially increasing liquidity and expanding the shareholder base. CEO Fabio Chianelli noted the company is focused on developing psychedelic pharmaceuticals for neuropsychiatric and neurological diseases, including novel delivery methods for substances like ketamine and psilocybin.
PharmaTher Inc., a subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), has partnered with the Terasaki Institute to develop a microneedle patch for delivering psychedelic pharmaceuticals like psilocybin and MDMA. This innovative technology utilizes biodegradable GelMA material, aiming to address issues with oral and injection methods. PharmaTher's goal is to gain FDA approval for treatments targeting mental health and neurological disorders through this delivery system, enhancing patient compliance and treatment outcomes.